Assessment of factors affecting the mental condition of patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors

被引:2
|
作者
Gibek, Katarzyna [1 ]
Sacha, Tomasz [2 ]
机构
[1] Jagiellonian Univ Med Coll, Sw Anny St 12,Room 7a, Krakow, Poland
[2] Jagiellonian Univ Med Coll, Chair & Dept Hematol, Krakow, Poland
关键词
cancer; leukemia; psychiatric disorders; QUALITY-OF-LIFE; PSYCHIATRIC MORBIDITY; CANCER; DEPRESSION; ANXIETY; ADJUSTMENT; SYMPTOMS; DISTRESS; PREDICTORS; DISORDERS;
D O I
10.12740/PP/OnlineFirst/130264
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
Aim. The aim of the study was to make a general assessment of mental health, including signs of somatization, depression, anxiety, and functional disorders, in patients with chronic myeloid leukemia (CML) treated with tyrosine kinase inhibitors (TKIs) and to assess the impact of factors such as the duration of the disease, side effects of therapy, age, and gender on the occurrence of the above-mentioned disorders. Another goal was to identify patients at risk of developing mental disorders. Method. The study involved 91 patients and was conducted at the Hematology Clinic of the University Hospital in Krakow. The following questionnaires were used to assess mental health: survey created by the author, David Goldberg's questionnaire GHQ-28, and the four-dimensional 4DSQ, measuring four dimensions of the mental condition. Results. The average level of the mental condition of the studied group was demonstrated. 29 people with mental disorders were identified. Women and people living alone obtained worse results in almost all dimensions of the questionnaires. The analysis revealed that factors such as age, number of side effects and gender significantly affect mental disorders in the studied group. A significant and positive correlation has been found between the number of side effects and the presence of somatization signs. Mediocre correlations occurred between age and mental disorders and all dimensions of the GHQ-28. Conclusions. The obtained results indicate that attempts should be made to reduce side effects among CML patients. Visiting the psychologist to work on the acceptance of the disease, psychoeducation, behavioral therapy, and contact with a psychiatrist to consider the introduction of pharmacotherapy is recommended. All of these methods may improve a patient's quality of life.
引用
收藏
页数:15
相关论文
共 50 条
  • [31] Resistance to tyrosine kinase inhibitors in chronic myeloid leukemia
    Lion, T.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S3 - S3
  • [32] New tyrosine kinase inhibitors in chronic myeloid leukemia
    Martinelli, Giovanni
    Soverini, Simona
    Rosti, Gianantonio
    Cilloni, Daniela
    Baccarani, Michele
    HAEMATOLOGICA, 2005, 90 (04) : 534 - 541
  • [33] Dual tyrosine kinase inhibitors in chronic myeloid leukemia
    G Martinelli
    S Soverini
    G Rosti
    M Baccarani
    Leukemia, 2005, 19 : 1872 - 1879
  • [34] Genetics and tyrosine kinase inhibitors of chronic myeloid leukemia
    Bani Bandana Ganguly
    Nitin N. Kadam
    The Nucleus, 2019, 62 : 155 - 164
  • [35] Tyrosine Kinase Inhibitors for the Treatment of Chronic Myeloid Leukemia
    Tolomeo, Manlio
    Dieli, Francesco
    Gebbia, Nicola
    Simoni, Daniele
    ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, 2009, 9 (08) : 853 - 863
  • [36] New tyrosine kinase inhibitors in chronic myeloid leukemia
    Kantarjian, Hagop
    Cortes, Jorge
    CANCER INVESTIGATION, 2007, 25 : 41 - 43
  • [37] Estimated glomerular filtration rate changes in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors
    Yilmaz, Musa
    Lahoti, Amit
    O'Brien, Susan
    Nogueras-Gonzalez, Graciela M.
    Burger, Jan
    Ferrajoli, Alessandra
    Borthakur, Gautam
    Ravandi, Farhad
    Pierce, Sherry
    Jabbour, Elias
    Kantarjian, Hagop
    Cortes, Jorge E.
    CANCER, 2015, 121 (21) : 3894 - 3904
  • [38] Quality of life outcomes in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a controlled comparison
    Kristin M. Phillips
    Javier Pinilla-Ibarz
    Eduardo Sotomayor
    Morgan R. Lee
    Heather S. L. Jim
    Brent J. Small
    Lubomir Sokol
    Jeffrey Lancet
    Sara Tinsley
    Kendra Sweet
    Rami Komrokji
    Paul B. Jacobsen
    Supportive Care in Cancer, 2013, 21 : 1097 - 1103
  • [39] Effect of Age on NK Cell Compartment in Chronic Myeloid Leukemia Patients Treated With Tyrosine Kinase Inhibitors
    Rodrigues-Santos, Paulo
    Lopez-Sejas, Nelson
    Almeida, Jani Sofia
    Ruzickova, Lenka
    Couceiro, Patricia
    Alves, Vera
    Campos, Carmen
    Alonso, Corona
    Tarazona, Raquel
    Freitas-Tavares, Paulo
    Solana, Rafael
    Santos-Rosa, Manuel
    FRONTIERS IN IMMUNOLOGY, 2018, 9
  • [40] Prognostic significance of early molecular response in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors
    Yeung, David T.
    Mauro, Michael J.
    HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM, 2014, : 240 - 243